Post-COVID-19 Brain [¹⁸F] FDG-PET Findings: A Retrospective Single-Center Study in the United States

References

1. 1.↵
   Johns Hopkins Coronavirus Resource Center. Mortality Analyses. March 10, 2023. https://coronavirus.jhu.edu/data/mortality. Accessed December 5, 2022
2. 2.↵
   WHO Coronavirus (COVID-19). 2022. https://covid19.who.int/table. Accessed December 5, 2022
3. 3.↵
   1. Rudroff T,
   2. Workman CD,
   3. Ponto LLB

   . 18F-FDG-PET imaging for post-COVID-19 brain and skeletal muscle alterations. Viruses 2021;13:2283 doi:10.3390/v13112283 pmid:34835088

   CrossRefPubMed
4. 4.↵
   1. Havervall S,
   2. Rosell A,
   3. Phillipson M, et al

   . Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA 2021;325:2015–16 doi:10.1001/jama.2021.5612 pmid:33825846

   CrossRefPubMed
5. 5.↵
   1. Maltezou HC,
   2. Raftopoulos V,
   3. Vorou R, et al

   . Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis 2021;223:1132–38 doi:10.1093/infdis/jiaa804 pmid:33388780

   CrossRefPubMed
6. 6.↵
   1. Leung TY,
   2. Chan AY,
   3. Chan EW, et al

   . Short-and potential long-term adverse health outcomes of COVID-19: a rapid review. Emerg Microbes Infect 2020;9:2190–99 doi:10.1080/22221751.2020.1825914 pmid:32940572

   CrossRefPubMed
7. 7.↵
   1. Carfì A,
   2. Bernabei R,
   3. Landi F

   ; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603–05 doi:10.1001/jama.2020.12603 pmid:32644129

   CrossRefPubMed
8. 8.↵
   1. Goërtz YM,
   2. Herck MV,
   3. Delbressine JM, et al

   . Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020;6:00542-2020 doi:10.1183/23120541.00542-2020 pmid:33257910

   Abstract/FREE Full Text
9. 9.↵
   1. Graham EL,
   2. Clark JR,
   3. Orban ZS, et al

   . Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers.” Ann Clin Transl Neurol 2021;8:1073–85 doi:10.1002/acn3.51350 pmid:33755344

   CrossRefPubMed
10. 10.↵
    1. Mehta P,
    2. McAuley DF,
    3. Brown M, et al

    ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–34 doi:10.1016/S0140-6736(20)30628-0 pmid:32192578

    CrossRefPubMed
11. 11.↵
    1. Song E,
    2. Zhang C,
    3. Israelow B, et al

    . Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 2021;218:e20202135 doi:10.1084/jem.20202135 pmid:33433624

    CrossRefPubMed
12. 12.↵
    1. Mandal S,
    2. Barnett J,
    3. Brill SE, et al

    ; ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021;76:396–98 doi:10.1136/thoraxjnl-2020-215818 pmid:33172844

    Abstract/FREE Full Text
13. 13.↵
    1. Paterson RW,
    2. Brown RL,
    3. Benjamin L, et al

    . The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020;143:3104–20 doi:10.1093/brain/awaa240 pmid:32637987

    CrossRefPubMed
14. 14.↵
    1. Rubin R

    . As their numbers grow, COVID-19 “long haulers” stump experts. JAMA 2020;324:1381–83 doi:10.1001/jama.2020.17709 pmid:32965460

    CrossRefPubMed
15. 15.↵
    1. Fontana IC,
    2. Bongarzone S,
    3. Gee A, et al

    . PET imaging as a tool for assessing COVID-19 brain changes. Trends Neurosci 2020;43:935–38 doi:10.1016/j.tins.2020.10.010 pmid:33131922

    CrossRefPubMed
16. 16.↵
    1. Rodríguez-Alfonso B,
    2. Solís SR,
    3. Silva-Hernández L, et al

    . ¹⁸F-FDG-PET/CT in SARS-CoV-2 infection and its sequelae. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:299–309 doi:10.1016/j.remnie.2021.07.005 pmid:34340958

    CrossRefPubMed
17. 17.↵
    1. Martini AL,
    2. Carli G,
    3. Kiferle L, et al

    . Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients. Eur J Nucl Med Mol Imaging 2022;50:90–102 doi:10.1007/s00259-022-05942-2 pmid:35984451

    CrossRefPubMed
18. 18.↵
    1. Kas A,
    2. Soret M,
    3. Pyatigoskaya N, et al

    ; on the behalf of CoCo-Neurosciences study group and COVID SMIT PSL study group. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging 2021;48:2543–57 doi:10.1007/s00259-020-05178-y pmid:33452633

    CrossRefPubMed
19. 19.↵
    1. Guedj E,
    2. Campion JY,
    3. Dudouet P, et al

    . (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging 2021;48:2823–33 doi:10.1007/s00259-021-05215-4 pmid:33501506

    CrossRefPubMed
20. 20.↵
    1. Sollini M,
    2. Morbelli S,
    3. Ciccarelli M, et al

    . Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging 2021;48:3187–97 doi:10.1007/s00259-021-05294-3 pmid:33677642

    CrossRefPubMed
21. 21.↵
    1. Gandhi RT,
    2. Lynch JB,
    3. Rio CD

    . Mild or moderate Covid-19. N Engl J Med 2020;383:1757–66 doi:10.1056/NEJMcp2009249 pmid:32329974

    CrossRefPubMed
22. 22.↵
    1. Dietz M,
    2. Chironi G,
    3. Claessens YE, et al

    ; MONACOVID Group. COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome. Eur J Nucl Med Mol Imaging 2021;48:260–68 doi:10.1007/s00259-020-04968-8 pmid:32712702

    CrossRefPubMed
23. 23.↵
    1. Hua C,
    2. Merchant TE,
    3. Li X, et al

    . Establishing age-associated normative ranges of the cerebral 18F-FDG uptake ratio in children. J Nucl Med 2015;56:575–79 doi:10.2967/jnumed.114.146993 pmid:25745092

    Abstract/FREE Full Text
24. 24.↵
    1. Huang YC,
    2. Hsu CC,
    3. Huang P, et al

    . The changes in brain metabolism in people with activated brown adipose tissue: a PET study. Neuroimage 2011;54:142–47 doi:10.1016/j.neuroimage.2010.07.058 pmid:20682349

    CrossRefPubMed
25. 25.↵
    1. Friston KJ,
    2. Holmes AP,
    3. Worsley KJ, et al

    . Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1994;2:189–210 doi:10.1002/hbm.460020402

    CrossRef
26. 26.↵
    1. Jenkinson M,
    2. Bannister P,
    3. Brady M, et al

    . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002;17:825–41 doi:10.1006/nimg.2002.1132 pmid:12377157

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Jenkinson M,
    2. Smith S

    . A global optimisation method for robust affine registration of brain images. Med Image Anal 2001;5:143–56 doi:10.1016/s1361-8415(01)00036-6 pmid:11516708

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Penny WD,
    2. Friston KJ,
    3. Ashburner JT, et al

    . Statistical Parametric Mapping: The Analysis of Functional Brain Images. Elsevier; 2011
29. 29.↵
    1. Rosa PA,
    2. Cerami C,
    3. Gallivanone F, et al

    ; EADC-PET Consortium. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 2014;12:575–93 doi:10.1007/s12021-014-9235-4 pmid:24952892

    CrossRefPubMed
30. 30.↵
    1. Meyer PT,
    2. Hellwig S,
    3. Blazhenets G, et al

    . Molecular imaging findings on acute and long-term effects of COVID-19 on the brain: a systematic review. J Nucl Med 2022;63:971–80 doi:10.2967/jnumed.121.263085 pmid:35177424

    Abstract/FREE Full Text
31. 31.↵
    1. Niesen M,
    2. Trotta N,
    3. Noel A, et al

    . Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell. Eur J Nucl Med Mol Imaging 2021;48:1890–901 doi:10.1007/s00259-020-05154-6 pmid:33398411

    CrossRefPubMed
32. 32.↵
    1. Starke KR,
    2. Reissig D,
    3. Petereit-Haack G, et al

    . The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health 2021;6:e006434 doi:10.1136/bmjgh-2021-006434 pmid:34916273

    Abstract/FREE Full Text
33. 33.↵
    1. Statsenko Y,
    2. Zahmi FA,
    3. Habuza T, et al

    . Impact of age and sex on COVID-19 severity assessed from radiologic and clinical findings. Front Cell Infect Microbiol 2022;11:777070 doi:10.3389/fcimb.2021.777070 pmid:35282595

    CrossRefPubMed
34. 34.↵
    1. Goehringer F,
    2. Bruyere A,
    3. Doyen M, et al

    . Brain 18F-FDG PET imaging in outpatients with post-COVID-19 conditions: findings and associations with clinical characteristics. Eur J Nucl Med Mol Imaging 2023;50:1084–89 doi:10.1007/s00259-022-06013-2 pmid:36322190

    CrossRefPubMed
35. 35.↵
    1. Hosp JA,
    2. Dressing A,
    3. Blazhenets G, et al

    . Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain 2021;144:1263–76 doi:10.1093/brain/awab009 pmid:33822001

    CrossRefPubMed